A Saint Louis University researcher has received a grant to study the effects of treating post-traumatic stress disorder (PTSD) on cardiovascular and metabolic health. Jeffrey Scherrer, Ph.D., associate professor in Family and Community Medicine, received $2,348,320 from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH).

Veniti Inc. has closed on $25 million in Series D equity financing from Boston Scientific Corp. The funds will allow Veniti to complete the VIRTUS Trial and regulatory filing for the Vici Venous Stent System. The trial is being performed under a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE). The company also intends to expand product development and commercial operations.

September 9, 2016 — New research published Sept. 8 in the Open Access journal PLOS Biology reports the role of genes in congenital heart defects (CHD) is more complex than previously realized. The research conducted University of California Irvine biologists Anne Calof and Arthur Lander and colleagues also found that overall risk is determined by a combination of gene effects both inside and outside of the heart itself.

Carmat announced that the first implantation of its bioprosthetic artificial heart within the framework of the PIVOTAL study has been carried out. The implantation was conducted in accordance with the authorizations obtained from the ANSM (French national agency for the safety of medicines and health products) and CPP (patient protection committee).

Six-month preclinical data from trials of a Xeltis bioabsorbable aortic conduit were presented at the 2016 scientific meeting of the International Society for Applied Cardiovascular Biology (ISACB). The data was presented by Prof. Frederick Schoen, M.D., Ph.D., senior pathologist and executive vice chairman, Department of Pathology at Brigham and Women’s Hospital, and professor of pathology and health sciences and technology, Harvard Medical School.

September 8, 2016 — Prevencio Inc. announced that data on its new clinical and multi-protein panel to diagnose obstructive coronary artery disease was presented at the European Society of Cardiology (ESC) Congress. The data was presented by Principal Investigator James L. Januzzi, M.D., a practicing cardiologist at Massachusetts General Hospital and professor of medicine at Harvard Medical School. 

Technological and administrative obstacles are significantly cutting into available time for physicians to engage with patients. Nearly half a physician’s office day is now filled by data entry into electronic medical records (EHRs) and administrative desk work, according to a new time-motion study conducted by experts at the American Medical Association (AMA) and Dartmouth-Hitchcock healthcare system. The study results were published in the Annals of Internal Medicine.

Vascular Interventional Advances (VIVA)

September 7, 2016 — Toshiba America Medical Systems Inc. announced that its Aplio 500 Platinum ultrasound system will be used during a live case following the International Contrast Ultrasound Society (ICUS) Bubbles Conference, Sept. 8-9 in Chicago. The demonstration is meant to show the benefits of the recent U.S.

September 7, 2016 — St. Jude Medical Inc. (SJM) has filed a lawsuit against Muddy Waters Consulting LLC, Muddy Waters Capital LLC, MedSec Holdings Ltd., MedSec LLC and three individual defendants who are principals in these firms, for false statements, false advertising, conspiracy and the related manipulation of the public markets. This is in regards to a market report these firms released in August that claimed SJM’s implantable electrophysiology (EP) cardiac rhythm management devices were not secure against cyber attack and present a danger to patient safety.

Subscribe Now